• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Medulloblastoma

Medulloblastoma - 41 Studies Found

Completed : Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
: Recurrent Childhood Medulloblastoma
: 2010-11-10
:
  • Other: Laboratory Biomarker Analysis

Not yet recruiting : Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
: Untreated Childhood Medulloblastoma
: 2016-03-25
:
  • Drug: Cisplatin Given IV

Completed : Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma
: Untreated Childhood Medulloblastoma
: 2013-12-13
:
  • Drug: Vincristine Sulfate Give

Completed : GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
: Recurrent Childhood Medulloblastoma
: 2009-01-13
:
  • Drug: vismodegib Given orally

Completed : Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
: Untreated Childhood Medulloblastoma
: 2004-06-14
:
  • Drug: Cisplatin Given IV

Withdrawn : A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
:
  • Medulloblastoma, Childhood
  • Rhabdomyosarcoma

: 2012-09-28
:
  • Drug: LY2940680 Capsule admini

Completed : Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
:
  • Histologically Confirmed Medulloblastoma
  • Activation of the Soni
    : 2012-05-15
    :
    • Drug: vismodegib Hedgehog path

Completed : Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
:
  • Medulloblastoma
  • Neuroectodermal Tumor

: 2010-07-22
:
  • Biological: TTRNA-xALT TTRNA-x

Terminated : Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
:
  • Neuroblastoma
  • Medulloblastoma

: 2011-11-28
: Drug: TPI 287 Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Day
Completed : Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
:
  • Neuroblastoma
  • Medulloblastoma

: 2008-01-14
:
  • Drug: Nifurtimox 30mg/kg/day P

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.